Real-world experience with ocriplasmin indicates it is an effective, safe, and cost-effective treatment for symptomatic vitreomacular adhesion in properly selected eyes.
Peter W. Stalmans, MD
Advertisement
Articles by Peter W. Stalmans, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
5